“Treatment of HER2-expressing solid cancers remains an area with significant unmet need, and these preliminary Phase 1 clinical results for zanidatamab zovodotin (ZW49) show that it offers a ...

ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks ...

Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of people with metastatic gastroesophageal cancer (mGEA) alive for at ...

Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout at the ...

Zanidatamab, targeting HER2-positive cancers, shows promise with potential FDA approval in late 2024, aiming for $2 billion in annual sales at peak performance. Jazz's Q2 2024 financials reveal 4% ...

Zanidatamab is an HER2-targeted bispecific antibody with multiple novel mechanisms of action that has demonstrated ‘compelling’ anti-tumour activity in several HER2-expressing cancers ...

Analyst Robert Burns from H.C. Wainwright reiterated a Hold rating on Zymeworks (ZYME – Research Report) and keeping the price target at ...

New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2 ...

Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding ...

DUBLIN - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported promising results from a Phase 2 clinical trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in treating ...

DUBLIN - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported promising results from a Phase 2 clinical trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in treating advanced ...